TAS2R1
ENSG00000169777
Target class
GPCR
Chromosome
5
- Chemical probe available
- No
- Target name
- TAS2R1
- Gene name
- Taste 2 receptor member 1
- Gene symbol
- TAS2R1
- Protein name
- Taste receptor type 2 member 1 (T2R1) (Taste receptor family B member 7) (TRB7)
- T2R1
- TRB7
- Gene biotype
- Protein coding
- Gene family
- Taste 2 receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1.79
- Tissue specificity (Gini)
- 0.926
- Tissue specificity (tau)
- 0.991
- KEGG gene identifiers
- hsa:50834
- Protein interaction confidence
- 0.789636
- Protein interaction partners
- 11
- R-HSA-418594
- R-HSA-420499
- R-HSA-9717207
- End position
- 9712378
- Start position
- 9627347
- Chromosome
- 5
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.991251
- Expression inequality (Gini)
- 0.92635
Expression in transcripts per million
- Testis
- 1.79
- Brain - Caudate (basal ganglia)
- 0.16
- Brain - Nucleus accumbens (basal ganglia)
- 0.12
- Brain - Putamen (basal ganglia)
- 0.11
- Thyroid
- 0.07
Expression in transcripts per million
- Testis1.79
- Brain - Caudate (basal ganglia)0.16
- Brain - Nucleus accumbens (basal ganglia)0.12
- Brain - Putamen (basal ganglia)0.11
- Thyroid0.07
- Brain - Cerebellum0.07
- Brain - Cerebellar Hemisphere0.07
- Brain - Hypothalamus0.05
- Brain - Cortex0.04
- Brain - Frontal Cortex (BA9)0.04
- Brain - Hippocampus0.04
- Brain - Anterior cingulate cortex (BA24)0.03
- Brain - Substantia nigra0.03
- Adipose - Visceral (Omentum)0
- Bladder0
- Cervix - Ectocervix0
- Spleen0
- Muscle - Skeletal0
- Adipose - Subcutaneous0
- Uterus0
- Fallopian Tube0
- Breast - Mammary Tissue0
- Cervix - Endocervix0
- Liver0
- Stomach0
And 29 more, listed on the interactive page.
Biological processes
- GO:0001580
- GO:0005886
- GO:0016020
- GO:0008527
- GO:0033038
Related records
Trials (873)
- "The Once A Day Protease Inhibitor Regimens"
- 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
- A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Drugs (4)
- Dextromethorphan
- Nirmatrelvir
- Ritonavir
- Taurolithocholic acid